Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients.
Saag M, Balu R, Phillips E, Brachman P, Martorell C, Burman W, Stancil B, Mosteller M, Brothers C, Wannamaker P, Hughes A, Sutherland-Phillips D, Mallal S, Shaefer M; Study of Hypersensitivity to Abacavir and Pharmacogenetic Evaluation Study Team. Saag M, et al. Among authors: brothers c. Clin Infect Dis. 2008 Apr 1;46(7):1111-8. doi: 10.1086/529382. Clin Infect Dis. 2008. PMID: 18444831 Free article.
Population pharmacokinetics and maximum a posteriori probability Bayesian estimator of abacavir: application of individualized therapy in HIV-infected infants and toddlers.
Zhao W, Cella M, Della Pasqua O, Burger D, Jacqz-Aigrain E; Pediatric European Network for Treatment of AIDS (PENTA) 15 study group. Zhao W, et al. Br J Clin Pharmacol. 2012 Apr;73(4):641-50. doi: 10.1111/j.1365-2125.2011.04121.x. Br J Clin Pharmacol. 2012. PMID: 21988586 Free PMC article.
Advancing research and development of anti-infectives for children with a focus on antiretroviral therapy: A clinical development perspective.
Buchanan AM, Bekker A, Chandasana H, DeMasi R, Lulic Z, Ernest T, Brothers C, Min S, Ruel T, Tan LK. Buchanan AM, et al. Among authors: brothers c. Int J Antimicrob Agents. 2024 Oct;64(4):107306. doi: 10.1016/j.ijantimicag.2024.107306. Epub 2024 Aug 13. Int J Antimicrob Agents. 2024. PMID: 39146996 Free article. Review.
Pharmacokinetics, safety, and tolerability of dispersible and immediate-release abacavir, dolutegravir, and lamivudine tablets in children with HIV (IMPAACT 2019): week 24 results of an open-label, multicentre, phase 1-2 dose-confirmation study.
Brooks KM, Kiser JJ, Ziemba L, Ward S, Rani Y, Cressey TR, Masheto GR, Cassim H, Deville JG, Ponatshego PL, Patel F, Aurpibul L, Barnabas SL, Mustich I, Coletti A, Heckman B, Krotje C, Lojacono M, Yin DE, Townley E, Moye J, Majji S, Acosta EP, Ryan K, Chandasana H, Brothers CH, Buchanan AM, Rabie H, Flynn PM; IMPAACT 2019 Study Team. Brooks KM, et al. Among authors: brothers ch. Lancet HIV. 2023 Aug;10(8):e506-e517. doi: 10.1016/S2352-3018(23)00107-8. Lancet HIV. 2023. PMID: 37541705 Free PMC article. Clinical Trial.
49 results